| Literature DB >> 25495942 |
Ji-Ye Kee, Aya Ito, Shozo Hojo, Isaya Hashimoto, Yoshiko Igarashi, Koichi Tsuneyama, Kazuhiro Tsukada, Tatsuro Irimura, Naotoshi Shibahara, Ichiro Takasaki, Akiko Inujima, Takashi Nakayama, Osamu Yoshie, Hiroaki Sakurai, Ikuo Saiki, Keiichi Koizumi1.
Abstract
BACKGROUND: Inhibition of metastasis through upregulation of immune surveillance is a major purpose of chemokine gene therapy. In this study, we focused on a membrane-bound chemokine CXCL16, which has shown a correlation with a good prognosis for colorectal cancer (CRC) patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25495942 PMCID: PMC4300614 DOI: 10.1186/1471-2407-14-949
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Establishment of a cell line that stably overexpressed CXCL16. (A) The mRNA level of CXCL16 was analyzed by qRT-PCR. SL4-Cont and SL4-CXCL16 cells were cultured for 24 h and lysed to extract total RNA. These data were normalized to GAPDH and expressed relative to the SL4-Cont levels, which were assigned a value of 1. (B) Protein level of CXCL16. Cells were seeded in a 24-well plate and the supernatant was collected after 24 h for ELISA. *P <0.05, **P <0.01. All experiments were repeated at least three times.
Comparison of colon38 SL4-Cont and SL4-CXCL16 cells
| Gene name | Fold change | Gene symbol |
|---|---|---|
|
| ||
| Irf8 | 11.89 | Interferon regulatory factor 8 |
| Ccnd1 | 0.45 | Cyclin D1 |
| Casp8 | 0.39 | Caspase 8 |
| Bag4 | 0.33 | Bcl2-associated athanogene 4 |
| Bcl2l10 | 0.33 | Bcl2-like 10 |
| Casp9 | 0.33 | Caspase 9 |
| Mapk1 | 0.33 | Mitogen-activated protein kinase 1 |
| Bcl2l2 | 0.11 | BCL2-like 2 |
|
| ||
| Ltbr | 16.90 | Lymphotoxin B receptor |
| Tnfrsf22 | 5.83 | Tumor necrosis factor receptor superfamily, member 22 |
| Traf4 | 4.10 | TNF receptor associated factor 4 |
| MAP3K7 | 2.13 | Mitogen-activated protein kinase kinase kinase 7 |
| Ttrap | 2.01 | TRAF and TNF receptor associated protein |
| Irak1 | 7.84 | Interleukin-1 receptor-associated kinase 1 |
| Traf6 | 0.44 | TNF receptor associated factor 6 |
| Tnfaip2 | 0.41 | Tumor necrosis factor, alpha-induced protein 2 |
| IRAK4 | 0.36 | Interleukin-1 receptor-associated kinase 4 |
| Tnfrsf11a | 0.15 | Tumor necrosis factor receptor superfamily, member 11a |
|
| ||
| Tnni2 | 49.02 | Troponin I, skeletal, fast 2 |
| Myh3 | 34.13 | Myosin, heavy polypeptide 3, skeletal muscle embryonic |
| Pi16 | 23.76 | Peptidase inhibitor 16 |
| Tnni1 | 20.89 | Troponin I, skeletal, slow 1 |
Figure 2CXCL16 overexpression sensitizes SL4 cells to TNF-α-induced cell death. (A) Viability of SL4-Cont and SL4-CXCL16 cells following TNF-α stimulation. Cells were seeded in 96-well plates (2 × 103 cells) stabilized for 1 h and stimulated by TNF-α (10 ng/ml) for 24–48 h. *P <0.05, **P <0.01. (B) Annexin V assay. Cells were seeded in 6-well plates (2 × 105 cells) and treated with TNF-α (10 ng/ml) for 0-8 h. (C) Effects of CXCL16 expression on the TNF-α-induced apoptotic pathway in SL4 cells. (D) Effects of CXCL16 expression on the TNF-α-induced NF-κB and MAPK signaling pathways in SL4 cells. β-actin was used as a normalization control. All experiments were repeated at least three times.
Figure 3Correlation of CXCL16 and IRF8 expression in SL4 cells. (A) Expression of IRF8 in SL4-Cont and SL4-CXCL16 cells cultured for 24 h and analyzed by qRT-PCR. These data were normalized to GAPDH. (B) Knockdown of CXCL16 expression. SL4-CXCL16 cells were transfected with siRNA for 36 h to assess the expression of CXCL16 at the mRNA (upper panel) and protein (lower panel) levels. (C) Expression levels of IRF8 in SL4-CXCL16 using siRNA for control and CXCL16. β-actin was used as a normalization control. *P <0.05, **P <0.01. All experiments were repeated at least three times.
Figure 4Silencing of IRF8 expression by siRNA inhibited TNF-α-induced apoptosis in SL4-CXCL16. (A) Knockdown of IRF8 expression by qRT-PCR and Western blot analysis. (B) Viability of IRF8 knockdown cells stimulated with TNF-α. Cells were seeded in 96-well plates (2 × 103 cells) and stimulated with TNF-α (10 ng/ml) for 0–72 h and then viability was measured by the WST-8 assay. *P <0.05. (C) Annexin V assay. Cells were seeded in 6-well plates (2 × 105 cells) and treated with TNF-α (10 ng/ml). (D) Effects of IRF8 knockdown on TNF-α-induced apoptotic responses. C, si-Control; I, si-IRF8. All experiments were repeated at least three times.
Figure 5Tumor-derived CXCL16 inhibited liver metastasis by metastatic CRC cells. (A) Liver metastasis of SL4 cells. (B) Number of nodules on liver metastasis. Horizontal bar is the mean of the data points/group. (C) Tumor weight of liver metastasis. Similar results were obtained from three independent experiments (n = 8). *P <0.05. All experiments were repeated at least three times.
Figure 6Effect of 2-chloroadenosine on CXCL16-mediated inhibition of liver metastasis by SL4-CXCL16 cells. (A) M1 macrophage markers and TNF-α were detected by RT-PCR. GAPDH was used as the normalization control. N, normal; T, tumor. (B) Cytotoxicity of macrophage-derived TNF-α and recovery by TNF-α neutralizing antibody in SL4 cells. Cells (5 × 104 cells) were seeded in 24-well plates and a TNF-α neutralizing antibody added (2.5 μg/ml). RAW 264.7 cells (5 × 104 cells) were seeded in migration chambers and co-cultured. Cells were removed from the chambers and their viability was measured by WST-8 assay. *P <0.05, compared with control. # P <0.05, compared with RAW co-culture. (C and D) Restoration of liver metastasis by CXCL16 expression in a macrophage depletion model. 2-Chloroadenosine was dissolved in saline and injected intraperitoneally (50 μg/100 μl) 24 h before tumor inoculation. *P <0.05. All experiments were repeated at least three times.